Acarix Financial Statements From 2010 to 2024
| ACARIX Stock | SEK 0.32 0.01 3.03% |
Check Acarix AS financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Acarix AS's main balance sheet or income statement drivers, such as , as well as many indicators such as . Acarix financial statements analysis is a perfect complement when working with Acarix AS Valuation or Volatility modules.
Acarix |
Acarix AS Company Shares Outstanding Analysis
Acarix AS's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Acarix AS Shares Outstanding | 373.33 M |
Most of Acarix AS's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Acarix AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Acarix AS has 373.33 M of shares currently outstending. This is 106.79% higher than that of the Health Care Equipment & Supplies sector and 113.4% higher than that of the Health Care industry. The shares outstanding for all Sweden stocks is 34.71% higher than that of the company.
Acarix AS Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Acarix AS's current stock value. Our valuation model uses many indicators to compare Acarix AS value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Acarix AS competition to find correlations between indicators driving Acarix AS's intrinsic value. More Info.Acarix AS is rated fourth in return on equity category among its peers. It also is rated fourth in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Acarix AS by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Acarix AS's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Acarix AS Financial Statements
Acarix AS stakeholders use historical fundamental indicators, such as Acarix AS's revenue or net income, to determine how well the company is positioned to perform in the future. Although Acarix AS investors may analyze each financial statement separately, they are all interrelated. For example, changes in Acarix AS's assets and liabilities are reflected in the revenues and expenses on Acarix AS's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Acarix AS. Please read more on our technical analysis and fundamental analysis pages.
Acarix AB , a medical technology company, develops and commercializes diagnostic tests for cardiovascular diseases primarily in Europe, China, and the United States. Acarix AB was founded in 2004 and is based in Malm, Sweden. Acarix AB operates under Medical Devices classification in Sweden and is traded on Stockholm Stock Exchange. It employs 11 people.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Acarix Stock
Acarix AS financial ratios help investors to determine whether Acarix Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Acarix with respect to the benefits of owning Acarix AS security.